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Abstract
Cost-Effectiveness Analyses (CEAs) alongside randomised controlled trials (RCTs) are in-
creasingly often designed to collect resource use and preference-based health status data for the
purpose of healthcare technology assessment. However, because of the way these measures are
collected, they are prone to missing data, which can ultimately affect the decision of whether
an intervention is good value for money. We examine how missing cost and effect outcome
data are handled in RCT-based CEAs, complementing a previous review (covering 2003-2009,
88 articles) with a new systematic review (2009-2015, 81 articles) focussing on two different
perspectives. First, we review the description of the missing data, the statistical methods used
to deal with them, and the quality of the judgement underpinning the choice of these methods.
Second, we provide guidelines on how the information about missingness and related methods
should be presented to improve the reporting and handling of missing data. Our review shows
that missing data in within-RCT CEAs are still often inadequately handled and the overall level
of information provided to support the chosen methods is rarely satisfactory.
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1 Introduction
A well-known issue in Cost-Effectiveness Analysis (CEA), especially within a Randomised Con-
trolled Trial (RCT) setting, is the presence of large proportions of missing data in either or both
the outcome variables, i.e. the cost and the clinical effectiveness or utility measures. Removing
the unobserved cases (a method usually referred to as “Complete Case Analysis”, CCA) gener-
ally leads to a loss in efficiency and possible serious biases in the parameter estimates (Rubin,
1987; Schafer, 1997; Little et al., 2010; Molenberghs et al., 2015). Consequently, the final con-
clusions of the study may be strongly influenced by the way in which missingness is handled,
thus possibly reversing the decision about the cost-effectiveness of a new treatment compared
to the standard option (Manca and Palmer, 2006; ?).
While the problem of missing data is widely discussed in the statistical literature, it has
been relatively overlooked in the health economics one. Notable exceptions include Graves
et al. (2002); Briggs et al. (2003); Oostenbrink and Al (2005); Burton et al. (2007); Lambert
et al. (2008), mainly focussing on the cost measures; Richardson and Manca (2004); Wood et al.
(2004); Groenwold et al. (2012); Powney et al. (2014); Simons et al. (2015); Rombach et al.
(2016), with reference to health outcome measures; and Manca and Palmer (2006); Harkanen
et al. (2013); Diaz-Ordaz et al. (2014b); Faria et al. (2014), who consider both outcomes.
Interestingly, recent reviews on the methods applied in within-trial CEAs (Noble et al.,
2012; Diaz-Ordaz et al., 2014a) have concluded that CCA has historically represented the stan-
dard approach in health economics. As a result, we should be naturally sceptical about the
conclusions achieved by CEAs performed in a context where missingness is not addressed in
a principled way. This implies the incorporation of uncertainty about the missing values by
combining available information from the observed data with statistical assumptions to build
a well-defined statistical model. Within this framework, subsequent inferences are valid under
these assumptions, which in turn can be varied to test their impact on the decision-making.
The objective of this article is twofold: first, we review the methods used to handle miss-
ingness in within-trial CEAs between 2003-2015 by updating and extending the work of Noble
et al. (2012). This is done with a view to assessing whether the methods have evolved over time.
Second, we provide some guidelines about the way in which missingness should be analysed and
reported in the studies. The paper is structured as follows: §2 illustrates Rubin’s classification of
missing data mechanisms (Rubin, 1987). In §3 we provide a brief summary of the most popular
missingness methods, while §4 presents the methodology used to select the review’s articles and
the main results derived from the different analyses performed. In §5 we report a qualitative
analysis of the way in which information about the missing data is provided in the studies and
use these results to form some guidelines on the approach authors should follow when dealing
with missingness in CEAs. Finally, §6 summarises our findings and recommendations.
2 Missing Data Mechanisms
When analysing partially observed data, it is essential to investigate the possible reasons behind
missingness. This formally translates into an assumed missing data mechanism that is linked
to the data generating process.
We consider a sample of i = 1, . . . , n individuals and for each the relevant outcome is
indicated as yi, which is unobserved for some individuals. Typically, trial data also include a
set of covariates xi = (x1i, . . . , xJi), e.g. sex, age or co-morbidities. While in general these may
be partially or fully observed, in this section we consider only the latter case. In addition, we
define a missingness indicator mi taking value 1 if the i−th subject is associated with missing
outcome and 0 otherwise.
This setting can be modelled using two sub-models, or “modules”. The first module is the
missing data mechanism, denoted as Model of Missingness (MoM). It describes a probability
distribution for mi, as a function of some unobserved parameters pii and δ, defining the prob-
ability of missingness in the outcome variable yi. The second module is the data generating
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process of the outcome variable, denoted as Model of Analysis (MoA). This contains the main
parameters of interest (e.g. the population average costs and benefits) and describes a probabil-
ity model for the outcome yi. As a general example, we can think of a simple regression model
where yi ∼ Normal(µi, σ), and µi = β0 + β1xi. In this case, the parameters of the MoA are
β = (β0, β1) and σ.
The most accepted classification of missing mechanisms is given by Rubin (1987) and is based
on three classes, according to how the missingness probability in the MoM is modelled. A simple
graphical representation of the three classes is provided in Figure 1. Variables and parameters
are denoted by nodes of different shapes and colours according to their nature. Parameters
(β0, β1, σ, δ) are represented through grey circles. “Logical” quantities such as µi and pii,
which are defined as function of the parameters, are denoted by a double circle notation. Fully
observed variables (mi) are represented with a white circle while partially observed variables
(yi) are denoted by a darker grey circle. Finally, we show covariates (xi) as white squares to
indicate that they are fully observed and not modelled. Rounded rectangles are used to show
the extent of the two modules in terms of variables/parameters included. Arrows show the
relationships between the nodes, with dashed and solid lines indicating logical functions and
stochastic dependence, respectively.
FIGURE 1 HERE
Figure 1 (a) illustrates the class of ‘Missing Completely At Random’ (MCAR), in which the
probability of missingness is fully independent of any other partially or fully observed variable.
Consequently, in Figure 1 (a) MoA and MoM are not connected and pii does not depend on any
quantity in the MoA. This amounts to assuming that there is no systematic difference between
partially and fully observed individuals in terms of the outcome yi. In other words, in this case
we would be assuming that observed cases are a representative sample of the full sample.
Figure 1 (b) shows a case of ‘Missing At Random’ (MAR), in which the missingness proba-
bility may depend on a fully observed variable. As a result, MoA and MoM are connected by
means of the predictor variable affecting both the mechanisms generating yi and mi. Because of
this relationship, the partially observed cases are systematically different from the fully observed
cases; crucially, however, the difference is fully captured by xi.
Figure 1 (c) provides an example of ‘Missing Not At Random’ (MNAR). This is characterised
by dependence of the probability of missingness on both the partially and fully observed vari-
ables. Thus, in Figure 1 (c) pii depends on both the fully observed predictor xi and the partially
observed outcome yi. This means that the difference between fully and partially observed cases
still depends on the missing values, even after taking xi into account. Therefore it is necessary
to make more structured assumptions about this relationship that go beyond the information
contained in the data.
While intuitively helpful, this framework may be too simplistic in some cases. Since the
scope of this section is to provide a broad overview for Rubin’s classification, we assumed the
simplest case where missingness is present in a single response variable only, which may not
hold in real applications. This is particularly likely in the context of CEA, in which we are
concerned with a multivariate outcome, made of suitable measures of clinical benefits and costs,
i.e. yi = (ei, ci). Missingness can occur for either or both the relevant outcomes and this
can lead to as many missingness mechanisms as the number of partially observed quantities
(covariate missingness must also be considered). Additional complexity is given by whether
data are obtained in a cross-sectional or longitudinal setting, static or time-varying covariates
and more importantly the possible correlation between variables and missingness mechanisms
and between the mechanisms themselves.
3 Methods to Handle Missing Data
There are many different statistical methods to account for missingness, each relying on different
assumptions. It is important to carefully select the method in line with the setting-specific
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assumptions we assume to hold. For the sake of simplicity here we only broadly categorise these
methods. More in depth and complete presentation and analysis can be found for example in
Schafer and Graham (2002); Molenberghs et al. (2015).
3.1 Complete Case Analysis
This is a popular method in within-trial CEA studies, despite its limitations due to the strong
assumption that only the fully observed cases are needed in order to correctly make inference.
The critical disadvantage is that missing cases are simply discarded, thus reducing efficiency
and possibly biasing the parameter estimates.
3.2 Single Imputation
Single Imputation (SI) methods replace the missing data with a single predicted value, such as
the unconditional or conditional mean or the last value observed for a given case. This category
includes Last Value Carried Forward (?), Linear Extrapolation (?) and Conditional Imputation
(?). Although sometimes valid, these methods are never recommended as they typically require
stronger assumptions than MCAR and always fail to take account of the uncertainty underlying
the imputation process, i.e. they do not recognise that the imputed values are estimated rather
than known.
3.3 Multiple Imputation
A more sophisticated method is Multiple Imputation (MI, Schafer, 1999). The underlying
idea is to fill-in each missing data with plausible simulated values, drawn from the conditional
predictive distribution of the missing given the observed values. Thus, the set of imputations can
properly represent the information about the missing values that is contained in the observed
data for the chosen model. This is repeated K times, leading to K imputed datasets that
can be analysed via complete-data methods. The individual estimates are then combined into
a single quantity, e.g. using Rubin’s rules (Rubin, 1987); this captures the variability within
and between imputations. However, the critical aspect is that valid inferences depend on the
correct specification of the imputation model in terms of variable selection, distributions and
correlations.
3.4 Sensitivity Analysis
Sensitivity Analysis (SA) is a technique used to determine how different input values in a
model will impact the output, under a given set of assumptions. When applied to missing
data this corresponds to exploring as many plausible missing data assumptions as possible
and then assessing how consistent results are across the different scenarios. In particular, it
is generally recommended to set MAR as the reference assumption and then explore different
MNAR departures from MAR, to assess the robustness of the results to different plausible
alternative missingness mechanisms. The purpose of such analysis is to account more fully for
the uncertainty about the missingness. Usually SA is implemented through more advanced
methods that are able to explicitly model a MNAR mechanism such as Selection or Pattern
Mixture Models (Molenberghs et al., 2015; ?).
3.5 Others
There is a wide list of possible alternatives that could be explored such as Inverse Probability
Weighting (?), Likelihood-based methods (McLachlan and Krishnan, 2008), Doubly Robust
(Bang and Robins, 2005) or Full Bayesian methods (??).
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4 Literature Review
4.1 Methods
Noble et al. (2012) (henceforth NHT) reviewed the methods used to handle missing cost mea-
sures in 88 articles published during the period 2003-2009. We extend their review, to include
missing effects. Further, we use NHT’s strategy to identify papers in the subsequent period, 1
April 2009 to 31 December 2015. Articles were considered eligible for the review only if they
were cost-effectiveness analyses within RCTs, used individual patient-level data and mentioned
missing data in the text. We relied on the search engines of three online full-text journal
repositories: Science-Direct.com, bmj.com, and The Database of Abstracts of Reviews of
Effects (DARE) and NHS Economic Evaluation Database (NHS EED). The key words used
in the search strategy were (cost effectiveness OR economic evaluation) AND missing
data AND trial AND (randomised OR randomized). The on-line databases identified 1129
articles most of which were duplicates. After abstract review, 128 articles were considered, of
which 81 fulfilled the eligibility criteria.
We present and compare the articles reviewed for the two periods by type of analysis per-
formed. First, we look at the base-case methods implemented, i.e. those used in the main
analysis embedding the assumptions about missing data. Second, we consider any alternative
methods discussed; when present, these assess the robustness of the results obtained in the main
analysis against departures from the initial assumptions on missingness.
4.2 Base-case Analysis
As shown in Figure 2 (a), NHT found that CCA was the most popular base-case method, used in
31% of the papers; 23% were unclear about the technique adopted. Single imputation methods
were well represented, with mean imputation and conditional imputation used in 10% and 9%
of the articles respectively. MI was found in 9% of the articles. Our analysis of the methods
for missing effectiveness measures shows a similar pattern in Figure 2 (c). CCA was used in
27% of the cases and with a sizeable proportion of papers unclear about the technique adopted
(24%). Single imputation methods are here dominated by LVCF (10%), while a slightly higher
proportion uses MI (15%).
In 2009-2015, MI replaces CCA as the most frequently used base-case method in both costs
and effects, at 33% and 34% respectively (Figures 2 (b) and (d)). However, CCA is still the
method of choice in many papers (15% for costs and 21% for effects). The proportion of papers
that are unclear about the chosen method is similar over the two time periods for costs, but
halves in the later period for effects.
FIGURE 2 HERE
4.3 Robustness Analysis
With the term robustness analysis we refer to the specific concept introduced in §3.4, whose aim
is to assess the impact of plausible alternative assumptions about the missing data on the results,
with respect to the base-case scenario. This implies varying the structural assumptions about
the missingness mechanisms underlying the model, as opposed to the more general definition
of sensitivity analysis, which concerns with varying lower level assumptions (e.g. about the
distribution associated with a variable in the model).
Despite having a key role for assessing uncertainty, in practice, robustness analyses are rarely
performed in CEAs. This poses an important question related to the reliability of the findings,
as they may be affected by the specific assumption about missing data. From both review
periods it seems that a robustness analysis is infrequently used and typically involves only one
alternative scenario. This is not likely to be an optimal choice as the main objective of this
analysis is to explore as many plausible alternative missing data assumptions as possible.
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NHT found that 75% (66/88) of the articles did not include any robustness analysis, with
the remaining papers typically performing an analysis by comparing CCA and MI. Similar
findings apply to missing effects, with about 76% (67/88) of the studies lacking any alternative
missing data method. Similarly in the 2009-2015 review, we observe no robustness analysis in
the majority of the articles for both costs (75% or 61/81) and effects (70%, 51/81).
Figure 3 provides a pictorial overview of the alternative methods used for cost and effect
data. For costs most articles describe no alternative analysis. In the earlier period, the choice
of alternative missingness methods seems well-spread across CCA, MI and the use of more than
one method, with a slightly more frequent adoption of MI. By contrast, in the later period,
more cases use CCA as a robustness method in combination with MI as the base-case method.
Figures 3 (c)–(d) describe the effects, with most of the articles not reporting any robustness
analysis and with a significant increase in MI analyses, opposed to a decrease in CCA, between
the two periods. We also observe a reduction over time in the number of unclear missing effects
method analyses. Excluding this category, there is a similar pattern to the cost graphs towards
CCA used as a robustness method in combination with MI as the base-case method.
FIGURE 3 HERE
5 Recommendations for Missing Data Analyses
We argue that in order to judge whether missing data in a CEA have been adequately handled,
a full description of the missingness problem, details of the methods used to address it and a
discussion on the uncertainty in the conclusions resulting from the missingness are required.
With this in mind, we have assembled guidelines on how information relating to the missing
data should be reported (Table 1). We define three broad categories (Description, Method,
Limitations). For each, information that we consider vital for transparency is listed under ‘key
considerations’, while other details that could usefully be provided as supplementary material are
suggested under ‘optimal considerations’. Comparing the information provided in the articles
in our review against this list, allows us to qualitatively assess the quality of the reporting of
how missingness has been handled in CEA in the two time periods.
To gain a fuller understanding of the current state of play, we also classify the articles
from the perspective of the strength of the assumptions about the missingness mechanism.
This is related to the choice of method, since each is underpinned by some specific missing data
assumption. We can view the quality judgement and strength of assumptions as two dimensions
providing a general mapping of how the missingness problem is handled. This applies to both
the level of knowledge about the implications of a given missingness assumption on the results
and how these are translated into the chosen method. Details of our evaluation of both aspects
are provided next, starting with the strength of assumptions.
5.1 Quality Evaluation Scheme
We group the methods into five categories, ordered according to the strength of the associ-
ated missingness assumptions. These are: Single Imputation (SI), typically requiring stronger
assumptions than MCAR to hold; Complete Case Analysis, usually associated with MCAR;
Multiple Imputation, generally based on MAR; and Unknown (UNK), a residual group in which
we classify studies that do not explicitly mention the method used. We associate this class
with the strongest level of assumptions, since the lack of any method description may implicitly
suggest (over)confidence in a small effect of missingness on the results. By contrast, we define
Sensitivity Analysis (SA) as the least restrictive approach, which can assess the robustness of
the results to different alternative missingness mechanisms.
FIGURE 4 HERE
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Using the list of key considerations in Table 1, first we determined whether no (all key
considerations absent), partial (one or more key considerations absent) or full (all key consid-
erations present) information has been provided for each component. From this we computed
a numerical score to summarise the overall information provided on missingness, weighting the
components in a ratio of 3:2:1. Finally, we converted the scores into grades A-E. Figure 4
shows the process and weights used. Although the importance between the different compo-
nents is subjective, we believe that the chosen structure represents a reasonable and relatively
straightforward assessment scheme.
TABLE 1 HERE
The resulting scores can be interpreted qualitatively as follows:
A (12) The highest quality judgement, identified by the upper thicker blue path in Fig-
ure 4, including only those studies that simultaneously provide all the key consider-
ations for all the components. It is the benchmark for a comprehensive explanation
and justification of the adopted missing data method.
B (9-11) Includes studies providing full details for either the description or the method and
at least partial information for the other components. Studies with no information
about the limitations are only included in this category if full detail is provided
for both the other components.
C (6-8) Studies for which information about missingness is not well-spread across the
components. All key considerations are provided either for the description or the
method, but with only a partial or no content in the other components.
D (3-5) Indicates a greater lack of relevant information about missingness. Despite possi-
bly including key considerations on any of the components, the information pro-
vided will at most be partial for the description in which case it will be combined
with a total lack of content on either the method or the limitations.
E (0-2) The worst scenario where the overall information about the missing data is con-
sidered to be totally unsatisfactory. No description is given and we can observe
at most only some of the key considerations for the method.
5.2 Grading the articles
Figure 5 gives a graphical representation of both aspects for the articles reviewed between 2009-
2015 in terms of the assumptions and justifications (quality scores) on missingness. In both
graphs, more studies lie in the lower than in the upper part, indicating that fewer studies can
be classified as high quality in terms of the considerations about missingness. This is highlighted
by a greater concentration of points at the bottom of the figures (grade E). As we move along
the vertical axis, this tends to reduce up to the top level (grade A), where only very few cases
are shown. Of particular interest is the (almost) total absence of articles that performed a
sensitivity analysis (SA), clearly indicating very slow uptake of this technique.
A shift along the vertical axis in the graphs indicates an increase in the level of understand-
ing about the implications on the results for different choices of the missing data assumptions.
Therefore, we can argue that an upward movement in the plot will always improve the justifi-
cation of a specific assumption. However, to be able to follow this path we may have to rely on
more sophisticated methods that can match the given missingness assumption, i.e. if we think
our data are MNAR, then CCA assumptions are less likely to hold. The aim of an optimal
analysis should be to select a method that can be fully justified by matching the description of
the missing data problem to the assumptions underpinning the chosen method, i.e. map onto
the upper section of the graphs.
FIGURE 5 HERE
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6 Discussion
The objective of this paper is to critically appraise the issue of missing data analysis in within-
trial CEAs. In addition, we aim at providing a set of recommendations to guide future studies
towards a more principled handling and reporting of missingness. It is important that assump-
tions about missing data are clearly stated and justified. A robustness analysis is also important,
in order to explore the impact of plausible alternative missingness assumptions on the results
of the CEA. Often, a variety of techniques and analyses are used but not reported because
of space limits; on-line appendices and supplementary material could be used to report these
alternatives.
6.1 Review
Figure 2 highlights a shift in the most popular base-case missingness method from CCA to MI,
between the two periods of the review. The reasons behind this change may be related to some
drawbacks of CCA and the relatively recent wide development of software to perform MI.
First, even under a strong missing data assumption such as MCAR, CCA remains inefficient
because it ignores the predictive information contained in the partially observed cases. Non-
negligible rates of missingness on a few variables of interest may cause large portions of the
sample to be discarded. Second, CCA may cause serious biases in the parameter estimates.
Indeed, the condition for validity of CCA does not fit neatly into Rubin’s classes (White and
Carlin, 2010) in the important cases when: missing data affect the covariates; or the partially
observed outcome has a longitudinal nature.
Arguably, a very important factor in the increasing popularity of MI is the recent availability
of specific computer routines or packages (e.g. STATA or R; see ?). This probably led to some
abuse of the method as noted by Molenberghs et al. (2015). On the one hand, MI generally
allows the inclusion of a larger number of variables/predictors in the imputation model than
used in the analysis model, which potentially makes the assumption of MAR more plausible
and thus the overall analysis less likely to be biased. On the other, the performance of MI
depends on the correct specification of the imputation model (i.e. complexity in the analysis
model is reflected in the imputation model) and care is required in its construction. Although
essential, these details can be overlooked and are not often included in the reporting of the
analysis, undermining its reliability.
From the comparison of the base-case methods used for the costs and effects between 2009
and 2015 (Figure 2), we observe a marked reduction in the number of methods not clearly
described for the effects, compared to those for the costs. In CEAs we typically observe effect
data to be characterised by higher missing proportions than cost data, probably due to the
different methodology used to collect them. While clinical effectiveness measures are usually
collected through self-reported questionnaires, which are naturally prone to missingness, cost
measures rely more on clinical patient files which may ensure a higher completeness rate. In
addition, clinical outcomes are almost invariably the main objective of RCTs and as such they
are usually subject to more advanced and standardised analyses. Arguably, costs are often
considered as an add-on to the standard trial: for instance, sample size calculations are almost
always performed with the effectiveness measure as the only outcome of interest. Consequently,
missing data methods are less frequently well thought through for the analysis of the costs.
Our review identified only a few articles using more than one alternative method (Figure
3). This situation indicates a gap in the literature associated with an under-implementation of
robustness analyses, which may significantly affect the whole decision-making process outcome,
under the perspective of a body who is responsible for providing recommendations about the
implementation of alternative interventions for health care matters. Limiting the assessment
of missingness assumptions to a single case is unlikely to provide a reliable picture of the
underlying mechanism. This, in turn, may have a significant impact on the CEA and mislead
its conclusions, suggesting the implementation of non-cost-effective treatments. Robustness
analysis represents an important tool to properly account for more structured uncertainty related
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to the missing data and its implementation may provide a more realistic picture of the impact
that the assumptions have on the final conclusions.
6.2 Guidelines
Generally speaking, most papers in our review achieved an unsatisfactory quality score under
our classification (Figure 5). Indeed, our benchmark area on the top-right corner of the graphs,
is barely reached by less than 7% of the articles, both for cost and effect data. The opportunity
of reaching such a target might be precluded by the choice of the method adopted, which may
not be able to support less restrictive assumptions about the missingness, even when this would
be desirable. As a result, when simple methods cannot be fully justified it is necessary to replace
them with more flexible ones that can relax assumptions and incorporate more alternatives. In
settings such as those involving MNAR, sensitivity analysis might represent the only possible
approach to account for the uncertainty due to the missingness in a principled way. However, due
to the lack of studies either performing a SA or providing high quality scores on the assumptions,
we argue that missingness is not adequately addressed in most studies. This could have the
serious consequence of imposing too restrictive assumptions about missingness and affect the
outcome of the decision making process.
The classification of the studies into ordered categories (Figure 4) according to the informa-
tion provided on missing data (Table 1) is potentially a valuable tool for meta-analysis. It may
be reasonable for analysts to assign different weights to the individual studies based on their
specific information provided and methods adopted.
6.3 Conclusions
Given the common high proportion of missing cost and effect data in within-trial CEAs, many
study conclusions could be based on imprecise economic evidences. This is a potentially serious
issue for bodies such as the National Institute for Health and Care Excellence (NICE) who use
these evaluations in their decision making, thus possibly leading to incorrect policy decisions
about the cost-effectiveness of new treatment options.
Our review shows, over time, a significant change from more to less restrictive methods in
terms of the assumptions on the missingness mechanism. This is an encouraging movement
towards a more suitable and careful missing data analysis. Nevertheless, improvements are
still needed as only a small number of articles provide transparent information or perform a
robustness analysis.
Our guidelines could represent a valuable tool to improve missing data handling. By care-
fully thinking about each component in the analysis we are forced to explicitly consider all
the assumptions we make about missingness and assess the impact of their variation on final
conclusions. The main advantage is a more comparable formalisation of the uncertainty as well
as a better indication of possible issues in assessing the cost-effectiveness of new treatments.
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(a) Missing Completely At Random
(MCAR)
(b) Missing At Random (MAR)
(c) Missing Not At Random (MNAR)
Figure 1: Graphical representation of Rubin’s missing data mechanism classes, namely MCAR (a),
MAR (b) and MNAR (c). Variables and parameters are represented through nodes of different shapes and
colours. Parameters are indicated by grey circles with logical parameters defined by double circles, while
predictor variables are assumed fixed and drawn as white squares. Fully observed variables are denoted
by white circles, partially observed variables by darker grey circles. Nodes are related to each other
through dashed and solid arrows which respectively represent logical functions and stochastic dependence.
MoA=Model of Analysis, MoM=Model of Missingness.
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(a) Missing costs (2003-2009) (b) Missing costs (2009-2015)
(c) Missing effects (2003-2009) (d) Missing effects (2009-2015)
Figure 2: Review of the base-case methods used to handle missing cost and effect data between 2003-2009
and 2009-2015. Legend: Complete Case Analysis (CCA), Last Value Carried Forward (LVCF), Linear
Extrapolation (Lin Ext), Mean Imputation (Mean), Conditional Imputation (Cond), Multiple Imputation
(MI), any other method present in less than 4 articles (Others), unspecified method (Unclear). The
category Unclear includes those articles for which it was not possible, based on the text, to understand
the methodology used to deal with the missingness, while the category Others consists of the following
methods: Random draw, Linear Mixed Effects Model, Expectation Maximisation algorithm, Input-Case
Analysis, Assumed zeros, Two-part regression. The numbers to the right of the bars in the graphs are
the numbers of papers including the corresponding method in the base-case analysis.
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(a) Robustness Analyses Costs
(2003-2009)
(b) Robustness Analyses Costs
(2009-2015)
(c) Robustness Analyses Effects
(2003-2009)
(d) Robustness Analyses Effects
(2009-2015)
Figure 3: Comparison of methods used in the base-case analysis (x axis) and those used as alternatives
in a robustness analysis (y axis) for the articles between 2003-2009 and 2009-2015 for missing costs
and effects. Legend: unspecified methods (Unclear), other methods (Others), Linear Extrapolation (Lin
Ext), Last Value Carried Forward (LVCF), Mean Imputation (Mean), Conditional Imputation (Cond),
Complete Case Analysis (CCA), Multiple Imputation (MI).The category Unclear includes those articles
for which it was not possible, based on the text, to understand the methodology used to deal with the
missingness, while the category Others consists of the following methods: Random draw, Linear Mixed
Effects Model, Expectation Maximisation algorithm, Input-Case Analysis, Assumed zeros, Two-part
regression.
12
Figure 4: Diagram representation for the quality score categories. The table at the bottom shows how
scores have been weighted according to the information provided on each component. In accordance with
the table, different edges of the diagram correspond to different components. From left to right, the
initial edges are related to the Description, edges in the middle to the Method, and final edges to the
Limitations. Edges colour represents the different way the information provided in each analysis compo-
nent is evaluated: Red=No information (N), Light Blue=Partial information (P), Blue=Full information
(F). Final scores (0 - 12) with associated ordered categories (E - A) show the overall level of information
provided for each combination of component and content evaluation.
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Description
Key considerations
1. Report the number of individuals
with missing data for each variable
in the reported analysis by treatment
group.
2. Describe the missing data patterns
for all variables included in the
economic analysis (is missingness on
one variable associated with
missingness on another variable?, is
there a longitudinal aspect to the
data?)
3. Discuss plausible reasons why values
are missing (e.g. death).
Optimal considerations
1. Provide supplementary material
about the preliminary analysis on
missing-
ness (e.g. descriptive plots and tables)
1For example, in Multiple Imputation, state the imputation model specification and variables included, the number of imputations,
post imputation checks.
Method
Key considerations
1. Identify a plausible missingness
assumption for the specific patterns
and setting analysed.
2. State the method and software used
in the base-case analysis.
3. For more general methods provide
details about their implementation 1
4. Perform a plausible robustness
analysis; provide and discuss the
results.
Optimal considerations
1. Provide supplementary material
about the method implementation in
the base-case and robustness analysis
(e.g. software implementation code)
Limitations
Key considerations
1. Acknowledge and quantify the
impact of the missing data on the
results.
2. State possible weaknesses and issues
with respect to the method and
assumptions.
Table 1: List of the information content for each of the three components that we would like to observe
in the studies in order to achieve a full analysis reporting of the missing data. The contents are divided
into two subgroups: key and optimal considerations. The former are the statements to be considered as
mandatory for transparency when conducting an economic evaluation in the presence of missing data.
The latter are additional considerations that further extend the analysis reporting of the missing data
through supplementary materials. The lack of even one single key considerations is considered to be a
partial analysis reporting while a null analysis reporting is related to the absence of all key considerations.
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(a) Missing Cost Analyses (2009-
2015)
(b) Missing Effect Analyses (2009-
2015)
Figure 5: Joint assessment, in the reviewed articles between 2009-2015, for missing costs and effects, of
two components. The x-axis is the missingness method assumptions: Unknown (UNK), Single Imputation
(SI), Complete Case Analysis (CCA), Multiple Imputation (MI) and Sensitivity Analysis (SA). The y-
axis is the ordered classification for the quality judgement (scores) to support these assumptions: E, D,
C, B, A.
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